Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER_GOV 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 2Neoplasms 1Lung Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 45Carboplatin 33Bevacizumab 17liposomal doxorubicin 15Topotecan 12Taxes 10Gemcitabine 10Drug Therapy 6Cisplatin 6rucaparib 5mirvetuximab soravtansine 5Docetaxel 5Immunoglobulin G 4Doxorubicin 4Disulfides 4trebananib 3pembrolizumab 3olaparib 3Saline Solution 3Neoadjuvant Therapy 3Hyperthermic Intraperitoneal Chemotherapy 3Dexamethasone 3CP protocol 3niraparib 2cediranib 2Tamoxifen 2Specimen Handling 2Letrozole 2Glucose 2Cytoreduction Surgical Procedures 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Fallopian Tube Neoplasms × cediranib × Clear all
NCT02446600 2026-06-03

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
579 enrolled 17 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00532194 2015-09-23

ICON6

Medical Research Council

Phase 3 Unknown
486 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡